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Approximately 1.8 million adolescents were living globally with HIV in 2015.  HIV is the leading cause 
of death in adolescents in Africa and the second leading cause of death in adolescence worldwide. 
Perinatally HIV-infected (PHIV) adolescents often have chronic complications due to late access to 
antiretroviral therapy (ART) and ART side effects. There is relatively little information on their 
psychosocial outcomes although poor adherence has been described.   The aim of this study was to 
describe a cohort of perinatally HIV infected adolescents (PHIVA) attending Tygerberg Hospital, a 
tertiary hospital in the Western Cape in 2015. 
Material and Methods 
A retrospective descriptive study (folder review) describing all HIV- infected adolescents between the 
ages of 10 and 19 years attending the Infectious Diseases Clinic (IDC) during a 12 month period in 
2015 was performed. 
Results 
Ninety-eight of approximately 400 (25%) patients attending the Tygerberg Paediatric IDC were 
adolescents. Of these, 55 (56%) were female. Median age at first clinic visit was 4.9 years (IQR 1.5-
9.4). Median age at most recent clinic visit was 14 years (IQR: 10-19). The majority were WHO clinical 
stage 3 and 4 at diagnosis (74%). 
Twenty-eight (28%) adolescents were on their original ART regimen with no change in drug for side 
effects, failure or intolerance. Sixty-seven (68%) remained on their first regimen with a single drug 
switch due to side effects. Fifty of sixty -one adolescents (82%) starting on Efavirenz remained on it. 
Of 94 adolescents with a viral load available at last clinic visit, 71 (81%) were virologically suppressed.  
Viral genotyping was done in 7 of the 17 adolescents (41%) with viral loads above 1000 copies/ml. 
Only 3 (3%) were on third line drugs.   
Few adolescents had chronic medical complications: 23/98 adolescents (23%) were documented to have 
chronic lung disease (CLD) with 58 (59%) previously having Pulmonary Tuberculosis (PTB), 2 (2%) 
having had multidrug resistant (MDR) Tuberculosis and 1 (1%) having had Extremely Drug Resistant 
(XDR) Tuberculosis.  Four (4%) had cardiac disease, 1 (1%) had HIV related renal disease, 80 (80%) 
had documented dermatological complications. Forty-one (42%) had central nervous system 
complications such as seizures and neurodevelopmental delay. The median number of documented 
hospitalizations since diagnosis was 3 (IQR: 1-4) with no deaths in 2015.  
Sixty-eight percent (68%) of adolescents knew their HIV status. There was no documentation in 20 
(20%), while 11 (11 %) were not disclosed to.  For the latter, 7 had severe neurological disease.  Forty-
five (55%) attended mainstream school and 34 (34%) a special school/care centre.  Forty-six (47%) had 
failed a grade and 33 (33%) failed more than one grade. Five (5%) were on antidepressants.  Fifty-six 
(57%) had been referred to a social worker for complex psychosocial issues. 
When comparing those diagnosed at an age less than 10 years to those diagnosed older than 10 years 
the only statistic significant difference was a lower baseline absolute CD4 count  in those diagnosed 
after ten years of age (265 vs 554, p = 0,003). There was no difference in WHO staging at diagnosis, 
chronic complications or social issues.  
Conclusions 
Despite relatively late access to ART, adolescents had good virological outcomes that compare with 
international cohorts. There are fewer chronic medical complications than noted in other African 
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cohorts. However, there are significant psychosocial and educational issues and more focused 




Ongeveer 1.8 miljoen adolessente wêreldwyd het in 2015 met MIV geleef. 
MIV is die grootste oorsaak van sterfte by adolessente in Afrika, en die tweede grootste doodsoorsaak 
by adolessente wêreldwyd. Perinataal MIV-geïnfekteerde adolessente (PMIV’s) ervaar dikwels 
chroniese komplikasies weens vertraagde toegang tot antiretrovirale behandeling (ARV’s) sowel as die 
newe-effekte daarvan. Tog is daar betreklik min inligting beskikbaar oor hulle psigososiale uitkomste, 
hoewel adolessensie ’n risikofaktor vir ARV-versuim kan wees. Die doel van hierdie studie is om die 
uitkomste van ’n kohort PMIV-adolessente te beskryf wat in 2015 by Tygerberghospitaal, ’n tersiêre 
hospitaal in die Wes-Kaap, behandel is. 
Materiaal en metodes 
’n Retrospektiewe beskrywende studie (pasiëntelêerstudie) is uitgevoer om alle MIV-geïnfekteerde 
adolessente tussen 10- en 19-jarige ouderdom te beskryf wat in 2015 oor ’n tydperk van 12 maande by 
die Infeksiesiektekliniek van Tygerberghospitaal behandel is. 
Resultate 
Van die sowat 400 pasiënte wat by Tygerberghospitaal se Pediatriese Infeksiesiektekliniek behandel is, 
was 98 (25%) adolessente. Van hierdie 98 adolessente was 55 (56%) vroue. Die mediaanouderdom van 
die adolessente met hulle eerste kliniekbesoek was 4,9 jaar (interkwartielafwyking 1,5-9,4), en 14 jaar 
(interkwartielafwyking 10-19) met hulle mees onlangse besoek. Met diagnose was die meeste 
adolessente (74%) in fase 3 en 4 van die Wêreldgesondheidsorganisasie se MIV-klassifikasiestelsel. 
Agt-en-twintig (28%) was ten tyde van die studie steeds op hulle aanvanklike ARV-regime, sonder 
enige middelveranderinge weens newe-effekte, ondoeltreffendheid of intoleransie. Sewe-en-sestig 
(68%) was steeds op hulle eerste regime met ’n enkele middelverandering weens newe-effekte. Sewe 
uit die 17 adolessente (41%) met virale ladings meer as 1000 kopiee/ml het gekwalifiseer vir virale 
genotipering, die res was waarskynlik as gevolg van swak nakoming.  Slegs drie (3%) was op 
derdeliniemiddels. Vyftig van 61 (82%) adolessente wat efavirens begin gebruik het, het daarmee 
voortgegaan. Van die 94 vir wie daar met die mees onlangse kliniekbesoek ’n virustelling beskikbaar 
was, was 71 (81%) virologies onderdruk.   
Min adolessente het chroniese mediese toestande ontwikkel: Drie-en-twintig uit 98 (23%) het volgens 
hulle lêers aan chroniese longsiekte gely. Voorheen het 58 (59%) pulmonêre tuberkulose (PTB), twee 
(2%) multimiddelweerstandige tuberkulose, en een (1%) uiters middelweerstandige tuberkulose gehad. 
Vier (4%) het aan hartsiekte gely, een (1%) het MIV-nefropatie gehad, 80 (80%) gedokumenteerde 
dermatologiese komplikasies, en 41(42%) komplikasies van die sentrale senustelsel, soos toevalle en 
vertraagde neuro-ontwikkeling. Die mediaangetal hospitalisasies sedert diagnose was drie (1-4), en 
geen adolessent het in 2015 gesterf nie.  
Wat onthulling betref, was daar volle onthulling teenoor 67 (68%) adolessente; vir 20 (20%) was daar 
geen dokumente nie, terwyl daar teenoor 11 (14%) geen onthulling was nie. Sewe van die 11 teenoor 
wie daar geen onthulling was nie, het aan ernstige neurologiese siekte gely. Vyf-en-veertig (55%) het 
na hoofstroomskole gegaan en 34 (34%) na spesiale skole/sorgsentrums. Ses-en-veertig (47%) het een 
graad en 33 (33%) meer as een graad gedruip. So ver vasgestel kon word, was vyf (5%) op 
antidepressante. Ses-en-vyftig (57%) is vir psigososiale kwessies na ’n maatskaplike werker verwys. 
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“n Vergelyking is getref tussen die adolessente wat voor die ouderdom van 10 jaar gediagnoseer is 
teenoor diegene wat na die ouderdom van 10 jaar gediagnoseer is en die enigste statisties betekenisvolle 
verskil was ‘n laer basislyn absolute CD4 telling in diegene ouer as 10 jaar (265 vs 554, p = 0,003). 
Daar was geen verskil in Wereldgesondheidsorganisasie Klassifikasie stelsel, chroniese komplikasies  
en sosiale probleme  nie. 
Gevolgtrekkings 
Ondanks vertraagde toegang tot ARV’s  toon die adolessente betreklik goeie uitkomste wat ooreenstem 
met internasionale kohorte. Daar is minder chroniese mediese komplikasies as in ander Afrikakohorte. 
Tog beleef dié kohort beduidende psigososiale en opvoedkundige kwessies, wat slegs deur meer 
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Definitions and abbreviations: 
WHO: World Health Organization 
Adolescence: Defined by WHO as ages ranging between 10 years and 19 years. 
HIV:  Human immunodeficiency virus 
AIDS:  Acquired Immune-deficiency syndrome 
PHIV: perinatally HIV-infected 
PHIVA: perinatally HIV-infected adolescents 
PMTCT:  Prevention of mother-to-child transmission 
SA:  South Africa 
ARV: antiretroviral  
ART: antiretroviral therapy 
IDC: Infectious diseases clinic 
PJP: Pneumocystis Jiroveci Pneumonia 
SA: South Africa 
IV: intravenous 
UNAIDS: United Nations Programme on HIV/AIDS 
CLD: Chronic lung disease 
LIP: Lymphocytic Interstitial Pneumonitis 
DCMO: dilated cardiomyopathy 
HIVAN: HIV associated nephropathy 
TB: Tuberculosis 
APOL1: Apolipoprotein L1.   
CD4: cluster of differentiation 4.  This is a glycoprotein found on the surface of immune cells such as 
T helper cells 
*Only absolute CD4 counts were documented at first visit, no percentages available in folders.      
Viral Load: the number of copies of HIV RNA per millilitre of blood 
LDL: lower than detectable limit.  
*For the purpose of this study the definition of LDL was less than 40 copies/ml 
D4T: Stavudine 
TDF: Tenofovir 
LMIC: low-and middle income countries 
 
 




The definition of adolescence as defined by WHO, includes ages between 10 years and 19 years.  This 
is further divided into younger (10 – 14 years) and older (15 – 19 years) groups.1 
 In 2015, there were 1.2 billion adolescents between the ages of 10–19 years globally.2 Of these, 1.8 
million are living with Human Immunodeficiency virus (HIV), 80% of whom live in sub-Sahara 
Africa.3 These HIV- infected adolescents are a heterogeneous population of perinatally HIV-infected 
(PHIV) children that have survived to adolescence and those adolescents who have been infected with 
HIV between the age of 10-19 years.3  
The successful prevention of mother to child transmission (PMTCT) programme in South Africa (SA) 
has reduced perinatal infections in a significant way from >20% in 2004 to < 2% in 2015.4  This decrease 
along with early initiation of combination antiretroviral therapy (ART) in infants has further reduced 
the morbidity and mortality of PHIV children.  As a result of this, HIV is now evolving into a chronic 
disease.2  
The natural history of untreated vertically transmitted HIV is characterized by progressive 
immunosuppression.  The majority of children infected with HIV show progression of HIV infection 
to Acquired Immunodeficiency Syndrome (AIDS) and eventually death within first 5 years of age.5 In 
those children who acquire HIV vertically, infection, disease progression and mortality vary 
significantly in the manifestations.  Two basic patterns of disease progression have been identified:  
rapid disease progression where children reach a severe clinical stage within the first year of life or a 
more typical, slower progression with deterioration by the age of 5 to 6 years.6 Those in the early 
onset group present with Pneumocystis Jiroveci pneumonia (PJP) infection, encephalopathy and 
wasting syndrome. This group has a high mortality in comparison to those in the late onset group who 
present with recurrent bacterial infections, generalized lymphadenopathy and lymphocytic interstitial 
pneumonitis (LIP).6  
Up to 36% of perinatally HIV-infected adolescents (PHIVA), may be slow progressors and may have a 
mean survival of 16 years without ART7 however, the majority of PHIVA diagnosed in early 
adolescence have severe immunosuppression and a heavy burden of chronic complications, the most 
common being growth failure, lung and cardiac disease.8 The magnitude of this morbidity in PHIVA is 
poorly documented especially in those adolescents living in low and middle income countries (LMIC).  
The second decade of life, is a critical period in life as it represents a time of both vulnerability and 
potential. This time period is characterized by significant physical, emotional, social and psychological 
growth in a child’s life that is associated with the development of autonomy, increased impulsivity and 
risk taking. Adolescence is also a high risk period for non-adherence and associated virological failure.9 
Reasons for poor adherence are thought to be due to lack of knowledge about HIV, delayed disclosure 
of HIV status to the adolescent, being orphaned and mental health problems.10 
Some PHIVA were started on ART in early childhood and some may already be on second- or third-
line ART by the time they reach adolescence. This, in combination with the risk of developing drug 
resistance due to prior sub optimal regimens is of grave concern in view of the limited availability and 
cost of alternative regimens in resource constrained settings.11 
Retaining adolescents in care may be challenging. The prospect of lifelong treatment is daunting at any 
time in one’s life but for PHIVA this is by far more taxing than their usual challenges of developing 
maturity. In a recent publication investigating the research priorities for adolescent health in LMIC, 
HIV featured prominently.12  The recommended areas of research included how to improve adherence 
to treatment, identifying barriers to health care for HIV-infected adolescents, describing long term 
outcome and the prevalence of tuberculosis amongst this vulnerable population.12 
The aim of this study was to describe the clinical, psychosocial and virological outcomes, complications 
and ART history of the PHIVA attending a paediatric infectious diseases clinic in a middle income 
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country with high prevalence of HIV and TB.  A secondary outcome was to determine the possible risk 
factors for non-adherence to treatment and thirdly to compare clinical and virological outcome in those 
diagnosed below or above 10 years of age. 
 
Literature review 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) reports that there are 1.8 million HIV-
infected adolescents between 10 and 19 years of age.2 Of HIV-infected adolescents 80% are found in 
Eastern and Southern Africa.2 HIV is the leading cause of death in adolescents in Africa and the second 
leading cause of death for adolescents worldwide.12 Between 2005 and 2012, adolescents were the only 
population worldwide that saw an increase in AIDS-related deaths: 50% increase compared to 30% 
decline seen in general HIV population.13 It is estimated that in 2015 approximately 5700 new HIV 
infections (adults and children) occurred globally every day of which 66% were in Sub-Sahara Africa.11 
Of those infected daily, 400 were children less than 15 years of age.14  
There are 15 high burden countries but South Africa is home to 20% of the 1.8 million HIV infected 
adolescents. This means there are about 250 000-300 000 HIV infected adolescents in South Africa.15 
The population of adolescents living with HIV in SA consist of adolescents with perinatal infection 
who have survived to adolescence and those who acquired HIV at an older age through sexual activity, 
IV drug use or other less common modes of transmission.1 There is limited data on the health of South 
African adolescents, partly because of the age limits used in the District Health Information System.16 
Global HIV monitoring systems have been aggregating adolescents aged 10 – 14 years with all children 
less than 15 years and those aged between 15 and 19 years with all children older than 15 years. This 
has resulted in a challenge to monitor the adolescent HIV population as a unique target population with 
differences between the younger and older groups.16 
ARV triple therapy became available in South Africa in 2004. In the past ART guidelines for children 
necessitated clinical or immunological deterioration (CD4 counts less than 350 cells/mm3) to qualify 
for starting ART.   In 2013 new guidelines concluded that all HIV-infected children below the age of 
5 years regardless of the WHO clinical stage or if CD4 count equal or less than 500 cells/mm3 should 
be initiated on treatment.17 
 
Perinatally HIV-infected adolescents: 
Evidence from Zimbabwe suggests that there are increasing numbers of long-term survivors of mother-
to-child transmission who are reaching adolescence, the majority of whom are not yet in HIV care 
suggesting mother-to-child transmission as the predominant source of infection in adolescents 
presenting to acute primary care services.18 The average age at diagnosis in these patients is 8 years.18 
The relatively high CD4 cell counts in some of these previously undiagnosed cases raises the possibility 
that HIV progression may be very slow in some older long-term survivors.19  Children infected 
postnatally through breast feeding may be more likely to be slow progressors than those infected in 
utero or intrapartum.20  
PHIVA differ from those behaviourally infected in the fact that they are dealing with a chronic illness 
from a young age. These adolescents may have multiple chronic medical complications which include 
stunting, chronic lung disease, cardiac, neurological and dermatological complications.21 They have 
been attending clinic for many years and may have had multiple admissions to hospital.  The chronic 
disease and complications have a great impact on their emotional well-being and can lead to psychiatric 
illness.22 Due to poor adherence and previous limited ARV regimens many have been exposed to at 
least 3 ART classes as well as suboptimal regimens and are at risk of having resistant virus. Due to 
these factors health care services have a great challenge to maintain these adolescents in care.23  




One of the striking features of HIV infection in PHIVA is the high prevalence of chronic complications.  
Chronic lung disease (CLD), cardiac disease, neurocognitive disorders, skin and renal disease are 
important complications that have been described.23 
Chronic lung disease: 
Few studies have extensively examined the epidemiology of CLD in HIV-infected children and 
adolescents. Due to limited data, the full impact of HIV-related CLD cannot at present be calculated.24.  
CLD is a non-specific term that does not define the underlying pathology, but only suggests an 
underlying chronic lung condition.24 
Lymphocytic Interstitial pneumonitis (LIP) was the most common cause of CLD before ART was 
widely available. LIP responds to ART but if treatment is delayed it leads to long term complications 
such as bronchiectasis and cor pulmonale.  Another more serious complication is obliterative 
bronchiolitis, which unlike LIP has very little reversibility after starting ART.25 
Another important cause for CLD is recurrent pneumonia and tuberculosis (TB).25 TB causes airway 
destruction and leads to bronchiectasis.  In a case study of older children receiving ART complicated 
by bronchiectasis, 36% were previously treated for TB, with microbiological confirmation in only 
11%.24 This highlights the difficulty in confirming the diagnosis of TB in HIV-infected patients. These 
patients are however frequently treated for TB.25 In a Zimbabwe study of 116 PHIVA, more than 30% 
of adolescents had severe and disabling chronic respiratory symptoms. High-resolution CT scanning 
showed predominantly small-airways disease consistent with constrictive obliterative bronchiolitis, 
with LIP being an exceptional finding.26 According to a Western Cape cohort, lung function impairment 
is common in PHIVA on ART despite being controlled on treatment.27  The same study also found that 
previous PTB increases your risk for lung function impairment.27 CLD in HIV-infected children and 
adolescents requires heightened awareness to clinically identify children and adolescents at an early 
stage to prevent ongoing lung function loss.26 
Cardiac complications: 
Complications of cardiac disease include dilated cardiomyopathy (DCMO), pericardial effusion and 
left ventricular diastolic dysfunction. Few data are available on the burden of HIV associated cardiac 
pathology, the morbidity it causes and the outcome in HIV-infected adolescents living in Africa.28 
Renal complications: 
Black people might be at high risk for HIV associated nephropathy (HIVAN) because of the frequency 
of APOL1 gene variants associated with HIV nephropathy in African cohorts.29 HIV is also associated 
with decreased bone mineral content and density.29 Adolescence is an important period for bone mineral 
acquisition, therefore compromised bone mass can lead to premature osteoporosis.  Tenofovir has been 
associated with proximal renal tubular toxic dysfunction.29 
Growth and puberty: 
Stunting and pubertal delay is the hallmark of pediatric HIV infection and this distinguishes PHIVA 
from their uninfected peers and those infected during adolescence through sexual activity.30 Catch-up 
growth can be achieved after ART is initiated, but unfortunately those who begin ART in later childhood 








Progressive encephalopathy is well recognised in children and adolescents with HIV.  Data on the effect 
of ART on neurocognitive outcomes suggest that if ART is started as early as infancy the developmental 
outcome will be better.31 Asymptomatic PHIVA may have deficits that include shortfalls in cognitive 
and fine motor skills, memory and perceptual performance as well as mental processing and language 
abilities.  These are difficult to identify by routine testing.31  
 
Skin complications: 
Skin disease is a common and striking clinical feature amongst HIV-infected adolescents.  Common 
manifestations include papular pruritic eruption, angular stomatitis and molluscum contagiosum.32 That 
which is visible to everyone is of great concern to adolescents because resultant scarring is both 
disfiguring and stigmatizing.32 Social stigma can have a very negative impact on the well-being of HIV-
infected adolescents and is reason for concern, therefore the presence of cutaneous manifestations 
should be recognized and treated early.32 
 
Psychiatric complications: 
Mental health disorders, including general psychological distress, emotional, and behavioural 
problems, are a leading cause of health-related disability, affecting 10–20% of children worldwide.33 
A 2013 systematic review on mental health of adolescents living with HIV, found few studies 
describing the prevalence of psychiatric diagnosis in these adolescents.  New studies suggest that 
psychiatric disease such as depression and anxiety are more prevalent among PHIVA comparing to 
non-infected adolescents.34 In a 2000 study in United States, 53 % of HIV-infected adolescents had 
received a psychiatric diagnosis prior to HIV treatment and 44% experienced ongoing depressive 
disorders.34  
For the low- and middle-income countries in which the majority of the world’s HIV-infected 
adolescents live and where mortality is a major concern, enormous obstacles exist which prevent the 
implementation of healthcare infrastructure to address mental health.  Examples of these obstacles are 
lack of screening and lack of evidence for which interventions to implement.34 
 
Drug related complications: 
Antiretroviral drugs that were commonly used in the early ART era such as Stavudine (D4T) and 
Didanosine (DDI) which fall in the category of nucleoside analogues, have been associated with side 
effects that are related to mitochondrial toxicity whereas the newer medications like Tenofovir (TDF) 
and Abacavir (ABC) have fewer metabolic effects.35 D4T can cause lactic acidosis which is a 
potentially fatal adverse effect.  Another side-effect of D4T, lipodystrophy, is characterized by the 
loss of subcutaneous fat in the extremities, face and buttocks which can be irreverisible once 
advanced as well as stigmatizing and associated with decreased adherence.  Substituting D4T with 
ABC has proven to partially reverse changes in lipoatropy.35 Other side-effects of D4T are 
pancreatitis and distal sensory neuropathy were are indications for changing therapy. 
Efavirenz has been linked to neuropsychiatric effects, which include increased risk of suicidal 
ideation, encephalopathy, psychosis and ataxia.  The risk for toxicity has been associated with the loss 
of function polymorphisms of cytochrome 2B6, the main metabolising enzyme for EFV.  It is 
estimated that about 20% of sub-Saharan Africans are genetically slow metabolisers and may be at 
risk of EFV toxicity.35  
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Lopinavir/ritonavir, a protease inhibitor, is associated with gastrointestinal intolerance, 




Inflammation is being recognized as a significant consequence of HIV infection. Paediatric studies 
have now shown that PHIV-infected children have a high degree of inflammation related to 
uncontrolled HIV replication.36 The consequence of this increased inflammation includes vascular 
abnormalities which can result in heart disease, strokes, altered glucose metabolism, malignancy and 
neurologic disease.36 This inflammation is decreased but not stopped by ART.36 Given that HIV 
infection is lifelong, and with ART there is increased survival of PHIV-infected adolescents, the 




In Africa, social factors such as being orphaned, poverty and inconsistent guardianship can result in 
behavioural problems and psychiatric disorders. The orphan epidemic has increased alongside the HIV 
epidemic with almost 50% of AIDS orphans found to be adolescents.37 Due to the immediate medical 
concerns and the social and economic burden of HIV, families give little attention to the mental health 
needs of adolescents.22 These factors can affect an adolescent’s access to HIV care and treatment 
adherence. 
In low income countries, PHIV youth are born into families who have experienced severe 
discrimination and now have to cope with the added burden of HIV-related stigma.38 Poor adherence to 
ART leads to emergence of drug resistance and the risk of spreading drug-resistant HIV strains when 
adolescents become sexually active.39  The transition of adolescents from pediatric to adult HIV care 
services might further disrupt adherence due to adolescent anxiety, fear of the unknown, health care 
workers that have limited time for counselling and little experience of addressing adolescent-specific 
concerns.40  
Delayed disclosure of HIV status to the adolescent and a resultant lack of autonomy, substantially 
affects adherence.41  WHO recommends that disclosure occurs before 12 years of age, but needs to be 
applied to each individual.41 In a collaborative study between University of Oxford and Cape Town, 
they found that full disclosure to adolescents at an early age was associated with higher ART adherence 
and that pediatric disclosure can be done successfully in a low-resource context and in a range of 













1. Gaps in the literature 
Compared with infants and adults there is considerably less literature documenting the burden of HIV 
among adolescents and the tools for addressing their holistic health needs.  Most data comes from 
resource rich or very low income countries.  Few data is available on the spectrum and epidemiology 
of chronic disorders and outcomes associated with HIV infection in adolescents.   
 
2. Hypothesis: 
We hypothesize that the outcome, number of complications, treatment failure and HIV drug resistance 
of HIV-infected adolescents treated in a paediatric infectious disease clinic in a middle income country 
with a high prevalence of HIV, will differ from those reported from high income countries. We 
hypothesize that there will be increased morbidity in these adolescents due to more limited resources 
and a higher burden of infections such as TB. 
 A second hypothesis is that there is a difference in outcome between those that started ART below the 
age of 10 years and those starting treatment at age older than 10 years. 
 
Research question: 
A cross sectional analysis of perinatally HIV-infected adolescents in a paediatric infectious diseases 
clinic in the Western Cape, South Africa. 
 
4. Aim of the study  
The aim of this study will be to describe the demographic details, medical and psychosocial 
complications, drug regimens, drug resistance and virological outcome of HIV-infected adolescents 
treated in a pediatric IDC in the Western Cape, South Africa.   
 
5.  Primary outcomes: 
 To describe the demographic data, virological outcomes, medical and psychosocial 
complications of PHIV adolescents in a tertiary care clinic. 
 
6. Secondary outcomes: 
 To document the  antiretroviral (ART) drug regimens that adolescents were receiving in 2015 
 To document ART resistance  
 To document the use of ‘third line’ ART 
 To compare adolescents diagnosed above or below 10 years of age. 
 To identify possible risk factors for virological failure 
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Methods and Methodology: 
1. Study setting:   
The study was conducted at Tygerberg Hospital, a 319 pediatric bed hospital, situated in the Western 
Cape of South Africa.  Tygerberg Hospital is a tertiary care hospital with a pediatric Infectious Diseases 
ward and clinic. The clinic team comprises 2 dedicated pediatric nursing staff members, 3 medical 
officers, 1 HIV counsellor and 1 pharmacist, all of whom have been working at the clinic for more than 
10 years and have many other responsibilities. The staff is shared with the adult clinic but on specific 
days are allocated to the children’s clinic.  The team is assisted by 2 pediatric Infectious diseases 
specialists once a week. The clinic serves the Northern Metro sub districts, Eastern Tygerberg, 
Khayelitsha, West Coast, Cape Winelands and Overberg rural districts. 
The population of the Western Cape is estimated to be approximately 6 million people.38 The hospital’s 
drainage area includes the Northern Metropolitan sub districts, Khayelitsha, Eastern Tygerberg, West 
Coast, Cape Winelands and Overberg rural districts. 
The prevalence of HIV in the Western Cape is approximately 17% 39, a significant number to treat. 
Children with HIV are seen at all the surrounding clinics and hospitals and those with complicated 
disease are referred to Tygerberg Hospital.  The remainder of adolescents attending the clinic began 
treatment at young age or live nearby and have remained at the clinic. In most institutions the cut-off 
age for pediatric care is 13 years after which you will be transferred to adult care.  At the Tygerberg 
IDC, patients remain in pediatric care till they are emotionally ready for transition and according to 
family’s request/doctor’s discretion. 
 
2. Study design: 
Retrospective descriptive study describing all HIV infected adolescents between the ages of 10 to 19 
years attending the IDC at Tygerberg Hospital during a 12 month period. 
 
3. Study population: 
The total number of adolescents, aged between 10 years and 19 years, attending the Pediatric IDC in 
the year 2015.  
 
Inclusion criteria: 
 Age between 10 and 19 years 
 Confirmed HIV infection 
 Entered in the clinic database of the Pediatric Infectious Diseases Clinic 
 
Exclusion criteria: 
 Patients less than 10 years or older than 19 years  
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4. Data collection:  A list of patients that met the inclusion criteria was obtained from the Pediatric IDC 
database.  The patient’s medical folders which were available from the Pediatric IDC were then 
reviewed.  The data collected was recorded on a data collection sheet (see appendix A) 
 
Children who were infected through different methods but who were identified at an age less than 10 
years old or during follow up, were not excluded. 
Viral load was lower than detectable limit (LDL) if the value was less than 40 copies/ml.  CD4 counts 
were only available as absolute values, percentages not documented.       
Social worker referral was only documented if they were referred for social issues and did not include 
grant applications. 
 
5. Data Management: 
The data capture sheet was completed and loaded onto an electronic database (Microsoft Excel 2013) 
with the above variables. The researcher extracted all details from patient files and documented it on 
the data capture sheet.  Each adolescent was allocated a unique study number so that the data captured 
reflected no identifiable information. The data was then entered into MMed candidate’s personal 
computer with no identifying information. 
 
6. Data Analysis: 
Data was captured on the MS Excel spread sheets and with the help of the department of biostatistics 
data was analysed using Excel. The characteristics of the patients were described using standard 
descriptive analysis, including measures of central tendency (mean, median, proportions) and dispersion 
(standard deviations, interquartile ranges and 95% confidence intervals.) 
 
7. Statistical methods: 
Stata version 14 (StataCorp, Texas) was used to analyse the data. Descriptive analysis entailed 
summarising numerical data using medians and interquartile ranges in the case of non-normal 
distributions, and means and standard deviations if the data were normally distributed. Categorical 
variables were summarised using frequency tables and percentages by group. Comparisons between 
groups were analysed using Pearson’s chi square tests for categorical variables and Mann Whitney tests 
for continuous variables. Binary logistic regression analysis was undertaken to assess factors associated 
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8. Ethical and Legal considerations: 
The following ethical principles were adhered to during the course of this study: 
 
a) Social value:                                                                                                                                                    
At the time of the study, available data suggested that HIV-related deaths are increasing in 
adolescents whereas decreasing in all other groups. Adolescent-specific data are limited, which 
present a serious impediment to measuring and monitoring progress.  Not enough is known in order 
to develop strategies to improve their treatment outcomes. By doing this study we hope to develop 
strategies to improve their morbidity and mortality. 
b) Respect for persons: 
Only retrospectively collected data was analysed in this study.  There was no direct contact 
between the researcher and patients 
 
 
c) Privacy and confidentiality:  
No patient identifying data was used on the data-capture sheet, the data was collected 
anonymously using a unique study number. 
 
d) Independent review: 
The protocol was approved by the Health Research Ethics Committee (HREC) of the University 
of Stellenbosch, with ethics approval number S15/06/133. 
e) Informed consent: 
There was no contact between the researcher and subject as it was a retrospective folder review, 
there for a waiver of consent was granted by the HREC.  It was a retrospective anonymous audit, 
only the primary investigator retained the patient’s   identification, logged as a separate document 
in a secure location.  The audit contained no deviation from standard clinical practice. 
 
      
















Description of study population: 
Ninety-eight patients, of whom 55 (56%) were female, met the inclusion criteria. Race was not recorded.  
The median age of ART initiation was 7 years (IQR: 4/12 -17).  The median age at first clinic visit was 
4.9 (IQR: 1.5 – 9.4) years and at last clinic visit 14 (IQR: 10 – 19) years.  Fifteen (18%) were older than 
10 years at their first clinic visit.  The majority of adolescents were WHO Stage 3 disease (53%) and 
Stage 4 disease (21%) at diagnosis  There  was no difference  between the baseline WHO stage in 
adolescents diagnosed and started on treatment before 10 years and after 10 years of age (p=0.139) 
(Table 1).  WHO staging was not re-classified after treatment was started. The median CD4 count at 
first clinic visit was 513 cells/mm3 (IQR: 264-2246).  Of those diagnosed at 5 years and older (80/98) 
and where CD4 count at diagnosis was available (38/80), 8 had severe immunodeficiency, 8 advanced, 
7 mild and 15 no HIV associated immunodefiency according to WHO immune classification.    
 The median CD4 count in those below 10 years of age at diagnosis was 554 cells/mm3 (IQR: 314-
1006) versus 265 cells/mm3 (IQR: 133-321) in those diagnosed above  10 years of age (p=0.0033). 
(Table 5)  Viral load was not documented at first clinic visit as it was not part of South African National 
guidelines at the time most adolescents had their first visit.   
At last clinic visit the median CD4 count was 656 cells/mm3 ( IQR: 476-1650).  Viral load at last clinic 
visit was lower than detectable limit (LDL) in 81% of patients (Table 1).   
The median duration of follow-up was 8 years (IQR: 4-12).  The median number of clinic visits at the 
Tygerberg IDC was 65 (IQR: 24-100) visits per adolescent. Hospitalization episodes at Tygerberg since 
first clinic visit ranged from 0 to 4 episodes with a median of 3 admissions in total.  In those adolescents 
with more than 5 years of follow-up, the mean number of hospitalizations was one event.  From the 34 
(35%) patients hospitalized in the last 5 years, 27 (79%) were virologically suppressed at the time. Most 
hospitalizations were due to chronic medical conditions (chronic lung disease, neurological 
complications, HIV-associated renal disease and cardiomyopathy) and drug side effects (Abacavir 
hypersensitivity and Efavirenz neurological side-effects).  
 
Outcomes: 
No deaths were documented during 2015.  
Viral suppression: From 94 plasma HIV RNA levels available at last clinic visit, 76 (81%) adolescents 
were virologically suppressed.  Viral genotyping was done in 7 of the 17 adolescents (41%) with viral 
loads above 1000 copies/ml.  The most common resistance mutations are described in Table 3.  
ART initiation below 10 years of age (53/63) or older than 10 years (11/14) had no effect on viral 
suppression. (p=0.6) 
Adherence: This was monitored by clinic sister/nurse by means of a pill count at each visit. There was 
no consistent documentation of adherence by the doctor.  Forty-six of the 98 (47%) had mother/father 
as treatment supporter, followed by family member (30/98) and foster parent (22/98). Viral suppression 
was not influenced by the type of treatment supporter a patient had. (p=0.51)  
Risk factors for virological failure:  We did not identify any statistically significant associations with 
virological failure.  [School failure (p=0.09); recurrent hospital admissions (p=0.15); social issues 
(p=0.16); medical complications (p=0.7); foster care (p=0.89) and depression (p=0.9)] 
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Chronic disease related to HIV:   
The main causes of chronic morbidity are summarized in Table 4.  A large proportion of adolescents 
had PTB (59%).  The majority of patients were first diagnosed with PTB and subsequently the diagnoses 
of HIV was made.  Skin complications, pulmonary, cardiac and neurological complications were 
chronic diseases documented. Most patients (82%) had skin complications. Multisystem disease was 
common: skin and lung (23%), skin and heart (8%), skin and kidney (6%), skin and brain (49%), lung 
and heart (6%) while 11% had neurological as well as pulmonary complications. Six patients had 4 
system involvement involving skin, lung, heart and brain complications.   
Depression was documented in five patients (5%) and they were initiated on antidepressants. 
There was no difference in the number of lung (p=0.13), cardiac (p=0.51), CNS (p=0.5), skin (p=0.55) 
complications in those starting ARV’s older than 10 years and younger than 10 years. (Table5) 
There was no difference in chronic diseases related to HIV between the virologically suppressed and 
non-suppressed patients. [CLD: (p=0.8); cardiomyopathy: (p=0.24); cor pulmonale: (p=0.5); HIVAN: 
(p=0.18); skin: (p=0.14); HIV encephalopathy: (p=0.6)]. 
 
Anthropometry 
At first clinic visit 42% of patients were stunted (28% stunted and 14% severely stunted) and at last 
clinic visit 27% were stunted (15.6% stunted and 11.5% severely stunted) p=0.02. There was a trend to 
more stunting in those with later (after 10 years of age) than earlier HIV diagnosis, 7/15 (46%) versus 
23/62 (37%) (p=0.19).  At last clinic visit, 6 of 15 stunted patients (40%) were virologically suppressed, 
2 were not suppressed and 6 viral loads were unknown.  Of the 11 with severe stunting at last clinic 
visit, 8 (73%) were virologically suppressed. None of these had HIV associated chronic complications 
documented like CLD or renal failure.  Tanner staging was not routinely documented.  BMI improved 
with ART treatment. 
 
Psychosocial issues: 
Sixty-seven (68%) of patients were disclosed to and 20% (20/98) not known/documented. Disclosure 
was done by parents (42%), family members (31%) and foster parents (27%).  Of the 11 patients that 
were not disclosed to, 7 had significant neurological disease.  
More than half (55%) of the adolescents were attending a mainstream school while a third (34%) 
attended a special school or care centre. Forty-six (47%) of patients failed a grade and nearly 33% failed 
more than one grade.  There was no difference in type of school attendance (p=0.87) or number of failed 
grades (p=0.52) between patients diagnosed less than 10 years and those diagnosed older than 10 years.                                                                                                                                                                           
Five percent of patients were receiving family planning with 83% not documented/known.  Two 
adolescents were currently pregnant. 
Referral to a social worker was documented if the patients had complex social issues that needed to be 
addressed. This did not include ordinary referrals for financial assistance.   More than half (57%) of the 
adolescents were referred to social services for issues related to abuse (verbal/physical/sexual), neglect, 
care giver/family issues, depression and suicidal thoughts. 
 
 




Looking at the number of compounds patients were exposed to, the majority 47% (46/98) were on 3 
different NRTI drugs, 2 patients were exposed to 5 different NRTI drugs, 21 to 4 different drugs and 
29 to 2 NRTI’s. The most commonly used NRTI drugs were Stavudine, Lamivudine and Abacavir. 
Most patients were only on 1 NNRTI drug which was Efavirenz and of the Protease inhibitors most 
were only on Kaletra/Aluvia. 
Twenty seven (28%) were only ever on one regimen. These 27 adolescents never switched medication 
for drug side effects or because newer drugs became available (for example Abacavir replacing 
Stavudine) or because of failure.  Sixty-seven (68%) remained on their first regime with single drug 
switches for side-effects.  At last clinic visit, 61 (62%) were on a regimen containing Efavirenz and 29 
(30%) on an Aluvia based regimen. Three adolescents (3%) were on ‘third line drug regimens’ 
containing Darunavir and Raltegravir.  All three these patients had resistance testing.  Only 1 (1%) 
adolescent was on Lamivudine (3TC) monotherapy at last clinic visit (Table 2). Fifty of the 61 (82%) 
adolescents ever started on Efavirenz never discontinued the drug and were suppressed at last visit with 
an average duration of 6.5 years on the drug.  Eighteen of the 29 (62%) adolescents that started on 
Lopinavir/Ritonavir and never switched to an alternative drug, were suppressed at last visit with average 
duration of 3.8 years on the drug.  
Drug side-effects:  The most common drug side-effect was lipoatrophy due to Stavudine (D4T) in 40/56 
(71%) of patients.  D4T is no longer used in current regimens.  Four of the 83 (5%) adolescents ever 
exposed to EFV, developed gynecomastia and 4/83 (5%) developed CNS complications like dizziness, 
drowsiness or nightmares. Abacavir hypersensitivity was reported in 4/64 (6%) patients.  
Hypercholesterolemia was reported in 2/46 (4%) of patients on Lopinavir/Ritonavir based regimen.  






















The main finding was that, in 2015 viral suppression was achieved in 81% of the adolescents at 
Tygerberg IDC with only 3% requiring third line ART.  Furthermore, few adolescents had chronic 
medical complications and there were no documented deaths that year.  Another important finding was 
that 57% of the adolescents had psychosocial issues requiring intervention.  These findings are 
reassuring considering that adolescents attended a clinic with minimal extra resources, in a tertiary 
hospital in Western Cape.  
The majority (75%) of the cohort of PHIVA that are described started attending the IDC at a median 
age of 4.9 (1.5-9.4) years and remained in the clinic for 8 (IQR: 4-12) years.  Only 18% of the 
adolescents started ART after the age of 10 years. This older group of patients are similar to those 
reported from Zimbabwe whose average age was eleven years.43 This is not similar to studies reported 
from high developed countries where 62% of adolescent patients attending HIV-clinics were diagnosed 
and commenced on treatment prior to their first year of life.44, 45 Based on these factors, one would 
expect the outcome, medical complications and treatment success to differ in well-resourced countries 
compared to low income countries. This study however indicates that good outcomes and few medical 
complication can be achieved in a middle income country where adolescents are treated in government 
clinics with minimal extra resources.  It is highly likely that the outcomes will improve even further, in 
low and middle income countries as a greater proportion of HIV-infected children are diagnosed and 
started on treatment within the first few months of life. 
In a study from Zimbabwe the majority of adolescents were diagnosed with WHO HIV stage 3 or stage 
4 disease,43 similar to this study where those diagnosed older than 10 years, 53% had stage 3 and 21% 
stage 4 disease. In resource limited settings up to 75% of PHIV infected youth have CD4 counts below 
200 cells/mm3 at the time of diagnosis.43 This is illustrated by a study in Zimbabwe where adolescents 
had median CD4 count of 101 cells/mm3 (IQR: 35-197)].43 In contrast, at Tygerberg IDC the median 
CD4-T cell count at diagnosis was 513 cells/mm3 (IQR: 264-2246). This higher CD4 count is 
misleading because the majority of children were diagnosed not in the adolescent period but as children 
(where CD4 percentage is the preferred measure). In our cohort those diagnosed in the adolescent period 
had a median CD4 count of 265 which is similar to the Zimbabwean cohort. 
The encouraging viral suppression outcome (81% LDL at last clinic visit) may be due to the fact that 
most patients have been followed up over a prolonged period at the same clinic by the same dedicated 
pediatric team.  Adherence and drug side-effects are screened for on a regular basis and patients 
psychosocial needs are addressed as far as possible.  In many resource-rich as well as low income 
countries, adolescents are sometimes transferred to adult care services at a predefined cut off age when 
they are emotionally not ready which further disrupts adherence.46  
Many of the adolescents at the IDC (67%) are still on their first regimen, unchanged in 27 (28%), with 
few single drug switches made due to side-effects in the majority. Stavudine was replaced by Abacavir 
in the National guidelines in 2010 due to the side effect of lipoatrophy and children were systematically 
switched to Abacavir provided they were suppressed. In this cohort of adolescents 71% were 
documented to have lipoatrophy or lipodystrophy as a result of using Stavudine (Table 2). Only 3% 
were on third line drugs and one patient was on 3TC monotherapy at last visit. This finding is promising 
when comparing the results with an urban cohort of PHIVA in the United States where the adolescents 
had been exposed to a median of eight different ARVs across three classes due to resistance and 
toxicity.47  
 From the 17 patients not virologically suppressed, only 7 (41%) had resistance testing. The remainder 
were thought to be non-adherent and did not qualify for resistance testing.  The most common mutations 
are summarized in Table 3.  Low numbers of adolescents on ‘3rd line therapy’ is reassuring when 
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compared to well-resourced settings where they face challenges regarding extensive resistance.48,49 This 
however, still indicates that non-adherence is a problem in those that are failing ART. 
The majority of PHIV-infected youth in Sub-Sahara Africa have severe immunosuppression and a 
heavy burden of chronic complications, mainly growth failure, lung and cardiac disease.43 By contrast, 
approximately 80% of the PHIV infected adolescents in resource-rich countries have been on 
longstanding combination ART, many having initiated therapy when they were under two years old and 
therefore with fewer chronic complications.50 In this study  42% of patients were stunted at first 
presentation with some catch up growth after initiation of ART; with 27% stunted at last visit (p=0.02). 
In resource limited settings the incidence of stunting can be up to 60% at diagnosis.43 When the height 
for age in those diagnosed less than 10 years were compared to those older than 10 years it was found 
that there was no difference (p=0.19). Although catch-up growth can be achieved after initiation of 
antiretroviral treatment, children who begin treatment in later childhood are typically unable to regain 
their height potential therefor the best outcomes are in those children started on ARV’s in first years of 
life.51   
The prevalence of prior TB in this population was very high.  Most patients were first diagnosed with 
TB (53%) and subsequently the diagnosis of HIV was made. Fifty-nine (59%) patients were diagnosed 
with PTB and 17% with extra-pulmonary TB during the course of their disease. This is similar to the 
70% of patients diagnosed with TB in low income countries.43 Two patients (2%) had multidrug-
resistant TB and 1 patient (1%) had extensively drug resistant TB.  All patients were successfully treated 
for TB including the XDR-patient. 
Compared to LMIC where CLD has been documented in up to 86% of patients50, only 23% patients 
were labelled as having CLD with 10% diagnosed with bronchiectasis and 13% with LIP.  PTB had a 
strong association with both bronchiectasis (90%) and LIP (62%)  (p=0.12).  Accurately diagnosing 
CLD, in those adolescents who have it may prevent them from receiving multiple presumptive TB 
treatment courses.52 
Cardiac disease was only documented in a few patients, limited to cardiomyopathy (2%) and cor 
pulmonale (2%).  In a study in Harare, 67% of PHIVA had left ventricular hypertrophy, 31% right 
ventricular dilatation and 4% pulmonary hypertension.  Of note more than half of these patients were 
asymptomatic despite high frequency of echo abnormalities.53 It could be speculated that this could be 
the reason for the low incidence of cardiac disease as patients are not routinely screened for cardiac 
abnormalities.  
Skin complications were the most frequently documented complication with 82% of patients having 
had 2 or more skin complications of which papular pruritic eruption (50%) and dermatitis (43%) were 
the most common.  This correlates with patients in Zimbabwe where skin complications are common 
in 70%.54 
The median hospital admissions since diagnosis were 3 (IQR: 0-4).  In the last 5 years, most hospitalized 
patients (79%) were virologically suppressed.  Common reasons for admission were drug side-effects 
(ABC hypersensitivity and Efavirenz neurological complications) and chronic medical complications 
like CLD, seizures, DCMO and HIV related kidney disease.  
In resource rich settings there are high rates of admission for psychiatric reasons, but in resource poor 
settings there is little or no evidence of the psychological impact, depressive symptoms and psychiatric 
admissions for HIV-infected adolescents.55,56 The lack of screening programmes for mental health 
disorders, and the minimal healthcare infrastructure to address these issues are potential obstacles.57  
Psychosocial issues were reported in 57% of adolescents. Some reasons known for referral were 
behavioural problems in 11% and 5% known with depression.  Other psychosocial problems included 
referral to social services for issues with family dynamics, neglect, abuse, violence and extreme poverty.  
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Sexual identity issues and suicidal thoughts were reported and referred to psychologists and psychiatry. 
In LMIC the need for psychosocial support is evidently poorly explored. This area needs further 
investigation to determine the level of support needed. 
A very concerning finding was the poor documentation of contraceptive use with only 5% of patients 
known to be on contraception.  Pregnancy was documented in 2 patients.  This is an issue in both 
resource rich and poor settings that need urgent attention.58  
Strengths and weaknesses: 
This study presents limitations inherent to the retrospective method. It is also limited by the fact that it 
is a cross sectional analysis and data on transfer out or loss to follow up as well as morbidity and 
mortality prior to 2015 was not captured. Data on clinical examination and laboratory values were 
obtained from routine medical records and thus may not be complete.  We evaluated patients seen at 
tertiary referral hospital and the results/data cannot be generalized to smaller hospitals and clinics in the 
Western Cape.  Viral suppression was assessed based on viral load at last clinic visit and does not reflect 
the individual adolescent’s prior viral loads.  
A novel aspect of this study is that some patients were diagnosed at younger ages. This may have 
resulted in fewer chronic medical complications.  These findings indicate that a good outcome can be 
achieved in a setting with limited resources, where patients are managed in a holistic fashion and 
managed by the same dedicated clinicians until emotionally ready to transition to adult care.  The 
virological outcome findings compare to those in high income countries.  This study also revealed that 
psychosocial complications are a major issue and that there is a big need to address these issues in order 
to improve the outcome in this population group.   
 
Conclusions and Recommendations: 
Although there are fewer chronic medical complications than noted in other African cohorts, there are 
significant psychosocial and educational issues and more focused interventions are needed to address 
these. 
Virological outcomes in this cohort are relatively good and compare favourably to international cohorts 
although this is only a reflection of those PHIVA currently in care at the clinic. 















    
                                                              Data Capture Sheet: 
 
Patient ID number:   
Patient Folder number:                                                        
Questions: 
1.  Date of Birth:  
 
2. Date of Diagnosis: 
                                            
3. Male or female:                                             
Male:   Female:   
  
 
4. WHO stage at diagnosis: 
Stage 1 Stage 2 Stage 3 Stage 4 
    
         
5.  Date of initial Weight measurement:    
 Initial weight:  
   
6.  Date of most recent weight measurement: 
 Most recent weight:                                        
 
7.   Date of initial height measurement: 
  Initial height: 
 
8.   Date of most recent weight measurement: 
  Most recent height: 
 
9.  Initial BMI: 
 
10. Current BMI: 
 
11.   HIV drugs: 
Drug Name: Yes/No Date started: Date stopped: Reason for 
stopping: 
Abacavir/ABC:     
     
Lamivudine/3TC:     
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Efavirenz/EFV:     
     
Kaletra:     
     
Stavudine/D4T     
     
Zidovudine/AZT     
     
Didanosine/DDi     
     
Nevirapine:     
     
Aluvia     
     
Combivir     
     
Tenofovir/TDF     
     
     
 
           a)Start Regimen: 
           b) Current Regimen: 
A) Inappropriate Historical Regimen 1:     D4T,  3TC,  Ritonavir 
B) Appropriate Historical Regimen 1:        D4T,  3TC,  Kaletra 
C) Current Regimen 1 --  < 3 years old:     ABC,  3TC,  Kaletra 
D) Current Regimen1 --   > 3 years old:     ABC,  3TC,  Efavirenz 
E) 2nd Line:                                                      AZT,  3TC,  Kaletra 
F) 3rd Line:                                                      Darunavir, Raltegravir, AZT, TDF, 3TC,     Etravirine 
G) Other: 
        
12.  Date of initial CD4 count: 
 Initial CD4 count: 
 
11.  Date of most recent CD4 count: 
 Most recent CD4 count: 
 
12.  Date of initial HIV viral load: 
 Initial HIV viral load: 
 
13.  Date of most recent HIV viral load 
 Most recent HIV viral load 
 
14.  Date of transfer out(if applicable): 
 
15.  Loss to follow up: Loss to follow up if last clinic visit more than 6 months age 
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16 Resistance testing ever done? 
1. Yes 2. No 
  
 
17   Did doctor/parents disclose to patient: 
1. Yes 2. No 3. Unknown 
   
 
18  Does patient attend clinic with supporter:  
1. Yes 2. No 
  
 
 If yes, who? 
  
 
19  Type of School attendance: 
1.Normal medium school 2.special school 3.care centre 
   
 
20.  Ever failed grade?  
  
1. Yes 2. No 3. Not documented 
   
  




20  Contraception: 
1.Yes  2.No 3.Unknown 
   
 
21  Previous PTB? 
1. Yes 2. No 
  
 
22 Previous MDR TB? 
1. Yes 2. No 
  
 







4.  Skin 
disease 
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  Lung disease: 1-Bronchiectasis 
                         2-LIP 
                         3-PJP 
                         4-other 
                         5-nil documented 
 
       Cardiac pathology: 1- cardiomyopathy 
                                  2-pericarditis 
                                  3- Myocarditis 
                                  4- Other 
                                  5 nil documented 
                                  
         Renal Pathology: 1- HIVAN 
                               2- other 
                               3-nil documented 
 
Skin disease: 1- dermatitis 
                        2- tinea capitis, corporis 
                        3- papular pruritic eruption 
                        4- molluscum contagiosum 
                        5- other 
                        6 – nil documented 
 
CNS pathology: 1- HIV encephalopathy 
                            2- spasitic diplegia 
                            3- cerebral palsy 
                            4- seizures 
                            5- neurodevelopmental delay 
                            6 – ADHD 
                            7 – other 
                            8 – nil documented 




Depression:  1 = on antidepressants 
2 = not on antidepressants 
 
24   Total number of hospital admissions at Tygerberg Hospital: 
 
25  Social worker Referral: 
































Table 1:  Demographic data of the patients included in the study  
Characteristic: First clinic visit Last clinic visit 
Age   
  4.9 (1.5-10)  
 
14 (10-19) 
Diagnosed  at < 10yrs of age 65/98 (81)  
Female 55/98 (56) 




























   
15/92 (16)   
  6/92 (7) 
71/98 (77) 




  6/94 (6) 
69/94 (70)  










  25/90 (28)  
  13/90 (14) 
  52/98 (58) 
    8/98 (8) 
151 (107-170) 
  15/97 (16) 
  11/97 (12) 
  70/97 (72) 












  4/94 (4) 
  5/95 (5) 
  2/95 (2) 
  4/94 (4) 
19 (14-29) 
85/95 (89) 
  4/94 (4) 
 
All categorical variables were expressed as N (%) and all continuous as median (IQR) or mean (SD)  
Stunted:  Height for age below -2 Z score 
Severely stunted: height for age below the -3 Z score 
Wasted: weight for height below the -2 Z score 
Severely wasted:  weight for height below the -3 Z score 
BMI:  Body mass index 
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Table 2:  Drugs used at Tygerberg Infectious diseases clinic and number of reported side-effects 
of each drug:                     
Drug name: Ever exposed to drug 
N (%)  N/98 
Number of patients 
on specific drug at 
last clinic visit 
 N (%) 
Number of patients with 
drug previous side effects 
N (%) 
D4T 56 (57) 2 (2) 40(71) 
Lipodystrophy/lipoatrophy 
ABC 64 (65) 56 (57) 4 (6) 
ABC Hypersensitivity 
3TC 93 (97) 87 (89) 0 (0) 
EFV 83 (85) 61 (62) 4 (5) Gynaecomastia 
4(5)CNS complications 
AZT 34 (35) 19 (17) 8 (24) anaemia 
DDI 11 (11)   0 (0) 0 (0) 
ALUV/KAL 46 (47) 29 (30) 2(4.0) 
Hypercholesterolemia 
TDF# 16 (16) 15 (15) 1 (6) Bone mineral density 
decreased 
NVP   6 (6)   2 (2) 2 (33) hepatitis 
DAR   3 (3)   3 (3) 0 (0) 
RALTEG   2 (2)   2 (2) 0 (0) 
 
D4T: Stavudine; ABC: Abacavir; 3TC: Lamivudine; EFV: Efavirenz; AZT: Zidovudine; DDI: 
Didanosine; ALUV/KAL: Aluvia/Kaletra; TDF: Tenofovir; NVP: Nevirapine; Dar: Darunavir;  Ralteg: 
Raltegravir 














G190EQ  (1) 154VTAM   (2) 
T215YF     (2) 
 
K103NS  (2) V82ATSF  (4) 
M41L     (2) 
 
V106AM  (2) L76V   (2) 
D67N     (3)  M461IL  (2) 
             K70R     (1) 
  
NRTI: Nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase 
inhibitors; PI: Protease inhibitors 




Table 4:  Different medical complications documented: 
Medical complication: N (%)               N=98 
Prior Tuberculosis:  
Pulmonary Tuberculosis 58 (59) 
Extra pulmonary tuberculosis 17 (17) 
MDR TB  2 (2) 
XDR TB  1 (1) 
Lung complications:  
Bronchiectasis 10 (10) 
LIP 13 (13) 
PJP   1 (1) 
CLD 23 (23) 
Cardiac complications:  
Cardiomyopathy 2 (2) 
Pericarditis 0 (0) 
Myocarditis 0 (0) 
Cor Pulmonale 2 (2) 
Renal complications:  
HIV nephropathy 1 (1) 
Enuresis 6 (6) 
Skin diseases:  
Dermatitis 42 (43) 
Tinea 30 (31) 
PPE 49 (50) 
Molluscum contagiosum   6 (6) 
Impetigo 11 (11) 
Warts   4 (4) 
Herpes zoster   6 (6) 
Neurological complications:  
Encephalopathy   8 (8) 
Cerebral Palsy   3 (3) 
Seizures   9 (9) 
Neurodevelopmental delay 12 (12) 
ADHD   5 (5) 
Behavioural disorder 11 (11) 
  
 
MDR: multidrug resistant; XDR: extensively drug resistant; LIP: lymphocytic interstitial pneumonitis; 












Table 5:  Comparison of those that started ART before the age of 10 years and those that started 
ART after the age of 10 years. 
 Diagnosed < 10 
years:  N=64 
Diagnosed > 10 
years:  N=15 
P – value 
 
WHO staging at 
dx 
   
    Stage 1   1  (2) 1    (7)    
   0.139     Stage 2 11  (18)       6  (40)                                                                     
    Stage 3 38  (61) 7   (47) 
    Stage 4 12  (19) 1    (7) 
    
Anthopometry at 
diagnosis: 
   
Stunted  24 (39) 1 (7) 0,44 
Severely stunted   9 (15) 4 (30)  
Normal length 42 (68) 10 (67)  
    
Anthopometry at 
last visit: 
   
Stunted 12 (19) 3 (20) 0.8 
Severely stunted 11 (18) 4 (27)  
Normal length 59 (95) 11 (73)  
    
CD4count 554 265 0.003 
   
Failed grades 32  (49)   6  (40)   0.520 
Social issues 39  (60)   6  (40)   0.160 
School     
    Special school 15  (23)   4  (27)   0.870 
    Care centre   2    (3)   1    (7) 
Lung disease 19  (30)   5  (33)   0.130 
Cardiac disease   2    (3)   1    (7)   0.510 
Skin disease 56  (86) 12  (80)   0.550 
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